| Literature DB >> 31698849 |
Ana Carolina da Cruz Campos1,2, Francis M Cavallo2, Nathália L Andrade1, Jan Maarten van Dijl2, Natacha Couto2, Jan Zrimec3, Jerome R Lo Ten Foe2, Ana C P Rosa1, Paulo V Damasco4, Alex W Friedrich2, Monika A Chlebowicz-Flissikowska2, John W A Rossen2.
Abstract
Escherichia coli ST131 is a clinical challenge due to its multidrug resistant profile and successful global spread. They are often associated with complicated infections, particularly urinary tract infections (UTIs). Bacteriocins play an important role to outcompete other microorganisms present in the human gut. Here, we characterized bacteriocin-encoding plasmids found in ST131 isolates of patients suffering from a UTI using both short- and long-read sequencing. Colicins Ia, Ib and E1, and microcin V, were identified among plasmids that also contained resistance and virulence genes. To investigate if the potential transmission range of the colicin E1 plasmid is influenced by the presence of a resistance gene, we constructed a strain containing a plasmid which had both the colicin E1 and blaCMY-2 genes. No difference in transmission range was found between transformant and wild-type strains. However, a statistically significantly difference was found in adhesion and invasion ability. Bacteriocin-producing isolates from both ST131 and non-ST131 lineages were able to inhibit the growth of other E. coli isolates, including other ST131. In summary, plasmids harboring bacteriocins give additional advantages for highly virulent and resistant ST131 isolates, improving the ability of these isolates to compete with other microbiota for a niche and thereby increasing the risk of infection.Entities:
Keywords: AmpC-beta-lactamase; E. coli; ST131; UTIs; bacteriocins; plasmids; virulence
Year: 2019 PMID: 31698849 PMCID: PMC6920910 DOI: 10.3390/microorganisms7110534
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Bacterial isolates, their ST types, serotypes and phylogenetic groups.
| Isolates ID | ST Type | No of Isolates | Serotype | Phylogenetic Group |
|---|---|---|---|---|
| 3218, 5332, 7018, 7104, 9260,3218,9581A, 5770D,6638, 1294D, 5848, 2102, 1710D, 9533D, 3528, 7078, 9893, 7974, 4233, 5420, 4006, 5976, 2206, 8565, 2724, 6202 | ST131 | 26 | O25:H4 | B2 |
| 2445A,7719,864,2441,666,9715,108,4953,605 | ST69 | 9 | O17/O44:H18, O17/O77:H18, O15:H18, O15:H2, O25:H18, O45:H45 | D |
| 0015, 6077, 9733D, 5217, 8874, 3188B, 8200 | ST10 | 7 | O107:H54, O9:H9, O128ab:H10, O9:H12, O89:H10, O12:H4 | A |
| 1843,0107D, 6022, 2986,2993, 7002 | ST648 | 6 | O1:H6 | B2 |
| 6050, 9602, 6161, 2877 | ST405 | 4 | O102:H6 | D |
| 3052, 9492, 7348, 2723A | ST73 | 4 | O6:H1, O22:H1 | B2 |
| 9668 | ST297 | 1 | O86:H49 | B2 |
| 9097 | ST95 | 1 | O50/O2:H7 | B2 |
| 6419 | ST414 | 1 | O16:H5 | B2 |
| 5038 | ST58 | 1 | O8:H25 | B1 |
| 5306 | ST641 | 1 | O30:H25 | B1 |
| 3921 | ST101 | 1 | O21:H21 | B1 |
| 7167 | ST1431 | 1 | O8:H19 | B1 |
| 6632D | ST453 | 1 | O23:H16 | B1 |
| 1825 | ST93 | 1 | O7:H4 | A |
| 7500 | ST744 | 1 | O89:H10 | A |
| 6492 | ST12 | 1 | O4:H5 | B2 |
| 9307 | ST91 | 1 | O39:H4 | B2 |
| 1643 | ST354 | 1 | O25:H34 | F |
Figure 1Bacteriocin activity among ST131. The graph shows the bacteriocin activity of the three bacteriocin-producer ST131 isolates against other isolates that belong to ST131, ST10, ST648, ST405, ST73, ST69, ST297 and ST414. The * indicates the singleton isolates. The dark blue hits indicate the isolates that were sensitive to bacteriocin and the grey hits indicate bacteriocin-resistant isolates.
Figure 2Bacteriocin activity among non-ST131 isolates. The graph shows the bacteriocin activity of non-ST131 isolates against isolates from different ST types. The * indicates the singleton isolates. Orange represents isolates that were sensitive to the bacteriocin produced by the non-ST131 isolates and grey represents the bacteriocin-resistant isolates.
Distribution of bacteriocin genes among clinical isolates.
| Bacteriocin Groups | Bacteriocin Genes | Activity | Bacteriocin Producer Isolates ( | Non-Bacteriocin Producer Isolates ( |
|---|---|---|---|---|
| B | Ia | Pore-forming | 13 | 0 |
| Ib | Pore-forming | 1 | 0 | |
| M | Peptidoglycan Synthesis inhibitor | 3 | 2 | |
| 10 | Pore-forming | 0 | 1 | |
| A | E1 | Pore-forming | 3 | 7 |
| E9 | DNase | 2 | 4 | |
| A | Pore-forming | 1 | 2 | |
| Pyocin S | DNase | 7 | 24 | |
| Microcin V | Membrane disruption | 4 | 1 | |
| Microcin B17 | Membrane disruption | 1 | 1 |
Figure 3ST131 plasmid sequence alignments using hybrid assemblies. (A) Sequence alignment of plasmid p5848A1 found in isolates 5332, 5848 and 7078 containing the colicin E1 gene. (B) Alignment of plasmid p5848A2 found in isolates 7078, 5332 and 5848, containing the beta-lactamase bla, the sugE and the colicin Ib genes. (C) Alignment of plasmid p5848A3 found in isolates 5332 and 5848, containing the colicin Ia and microcin V genes, the resistance genes dfrA5, tetA and tetR and the virulence genes iucA, sitA, iroB, iroC, iroD and iroE. Isolate 5332 is indicated in pink, 5848 in green and 7078 in light purple. In addition, blue indicates the coding sequence region (CDS), black indicates the GC content, yellow indicates regions with a positive GC skew, and dark purple yellow indicates regions with a negative GC skew.
Figure 4Growth rate of isolates with or without bacteriocin and resistance genes containing plasmids in the presence or absence of cefotaxime. Results showing the growth rate (UFC/mL) of each competitor. Squares, triangles and circles indicate replicates. No statistically significant difference was found when comparing growth rates of DH5α (wild type) and DH5α+ (transformant strain).
Results of the prediction of transfer range using origin-of-transfer.
| Plasmid ID | Nic Location | Orientation | MOB Subgroup | NIC | |
|---|---|---|---|---|---|
| P5848A1 | 2350 | RC | P | −92.6330 | <10−16 |
| P5848A1.2 | 8823 | F | P | −56.5174 | <10−16 |
| P5848A2 | 45897 | RC | P | −377522 | <10−16 |
| P5848A3 | 110908 | F | F | −48.8684 | <10−16 |
MOB: mobility groups; nic: relaxase enzyme nicking sites (region within the origin transfer). F, forward; RC, reverse complement.
Figure 5Competitive adhesion and invasion assay. (A) Adhesion to HEK-293 (human embryonic kidney cell line) calculated in CFU/mL. (B) Invasion of HEK-293 for the same isolates. In both assays, results obtained from the plasmid containing isolates 5332 and 5848 were compared with other ST131 clinical isolates (9581A, 2206, 0107D), with ST648 (2993), ST354 (1643), ST297 (9668) and ST69 (7719) isolates, and with both the parental DH5α and the transformant DH5α+ strains. The * indicates a statistically significant difference (p ≤ 0.05).